<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289935</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 23/18</org_study_id>
    <nct_id>NCT04289935</nct_id>
  </id_info>
  <brief_title>Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer</brief_title>
  <acronym>VISION I</acronym>
  <official_title>Vacuum Assisted Biopsy Immediately Before Surgery as an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer (VISION I): A Multicenter Prospective Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant chemotherapy (NAC) is common practice in the primary treatment of breast cancer,
      leading to a complete pathologic remission (pCR) of the tumor in more than 50% in aggressive
      tumor types. As NAC induces different response patterns, radiologic imaging is not
      sufficiently accurate in predicting residual disease. Because of this uncertainty, surgery is
      so far the only valid option to either ascertain complete response or to remove the complete
      residual disease.

      Vacuum-assisted biopsy (VAB) with the possibility of obtaining tissue of the former tumor
      center could contribute more reliably to detect any residual tumor or respectively, rule out
      residual disease. Ultrasound (US) or mammographically (MG) guided VAB will be used in this
      trial in order to detect residual tumor lesions in patients with radiological complete
      response (rCR) after NAC. The investigators will evaluate the diagnostic accuracy of the
      post-NAC VAB sample in comparison to the sample obtained in open surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoadjuvant chemotherapy (NAC), initially indicated to downstage tumors to achieve the option
      of breast conserving surgery, has lately become common practice in the primary treatment of
      breast cancer. The use of modern NAC regimens lead to a complete pathologic remission (pCR)
      of the tumor in more than 50% in aggressive tumor types.

      In general, it is difficult to predict pCR in the absence of invasive surgical techniques, as
      it depends on several factors such as biological subtype, the used chemotherapy regimen and
      anatomic stage. The most common imaging methods beside clinical examination are breast
      ultrasound, mammography and breast magnetic resonance imaging (MRI). As NAC induces different
      response patterns, radiologic imaging is not sufficiently accurate in predicting residual
      disease. Because of this uncertainty, surgery (and the standardized assessment of resected
      tissue) is so far the only valid option to either ascertain complete response or to remove
      the complete residual disease.

      Vacuum-assisted biopsy (VAB) with the possibility of obtaining tissue of the former tumor
      center could contribute more reliably to detect any residual tumor or respectively, rule out
      residual disease. Ultrasound (US) or mammographically (MG) guided VAB will be used in this
      trial in order to detect residual tumor lesions in patients with radiological complete
      response (rCR) after NAC. The investigators will evaluate the diagnostic accuracy of the
      post-NAC VAB sample in comparison to the sample obtained in open surgery.

      The main objective of the trial is to determine the diagnostic accuracy of the post-NAC VAB
      in determining pCR compared to open surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>multicenter, prospective, single arm, feasibility trial</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>Sensitivity is defined as proportion of true positive patients (Both VAB and surgery showing non pCR) given patients with non pCR assessed using surgical specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>Specificity is defined as proportion of true negative patients (Both VAB and surgery showing pCR) given patients with pCR assessed using surgical specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV)</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>PPV is defined as proportion of true positive patients given patients with non pCR assessed using VAB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value (NPV)</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>NPV is defined as proportion of true negative patients given patients with pCR assessed using VAB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy (ACC)</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>ACC is defined as the proportion of true positive and true negative patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical lymph node status</measure>
    <time_frame>max. 6 weeks after registration</time_frame>
    <description>Surgical lymph node status (positive vs. negative) is categorized by the pathologist according to surgical specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From US-guided VAB (max. 6 weeks after registration) until 2 weeks after breast surgery (max 1 day after VAB).</time_frame>
    <description>Proportion of patients with bleeding/hematoma causing immediate surgical intervention and breast infection, which are related to VAB.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy
rCR / near-rCR in MRI
Registration
US-guided VAB
Breast conserving surgery / mastectomy
Pathology examination 1. Preoperative VAB, 2. Surgical specimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vacuum assisted biopsy (VAB)</intervention_name>
    <description>The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before registration and
             prior to any trial specific procedures

          -  histologically confirmed invasive breast cancer with IHC luminal B (with or without
             overexpression or amplification of the HER2 receptor) and all ER negative (ER &lt; 10%)
             breast cancers

          -  Initial tumor size larger than 1 and less than 5 cm (cT1c to cT2), any N, M0

          -  Clipping of the primary tumor center prior to the start of neo-adjuvant chemotherapy

          -  Neo-adjuvant chemotherapy resulting in a radiological complete response or near
             complete response on MR-Imaging (confirmed within 28 days before or on registration)
             as described in the trial specific MR-Imaging instructions available on the SAKK
             portal

          -  Former tumor bed must be accessible for biopsy

          -  Female or male aged ≥ 18 years

          -  Adequate condition for breast cancer surgery

          -  Patients with a previously treated malignancy are eligible, when the risk of the prior
             malignancy interfering with either safety or efficacy endpoints is very low.

        Exclusion criteria:

          -  Metastatic breast cancer

          -  Multifocal/Multicentric breast cancer

          -  Inflammatory breast cancer

          -  Luminal-A types of breast cancers (ER ≥ 10% and PgR ≥ 10 % and G1 or 2, and/or Ki-67 ≤
             20%, HER2 negative) or low risk if assessed by a validated genomic prognostic test
             (e.g. Mammaprint, Endopredict, Oncotype or Nanostring)

          -  Distinct radiological sign of residual disease in the breast after neo-adjuvant
             chemotherapy in MRI

          -  Intra-/peritumoral microcalcifications larger than 2 cm at time of diagnosis

          -  Any local therapy (irradiation or surgery) to the currently treated breast prior to
             the trial intervention

          -  Contraindication for MRI

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, trial intervention and follow-up, affect patient compliance or
             place the patient at high risk from trial intervention-related complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Tausch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brust-Zentrum, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Aline Gerard, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Leo, MD</last_name>
      <phone>+41 56 486 36 36</phone>
      <email>cornelia.leo@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Cornelia Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Walter Weber, Prof</last_name>
      <phone>+41 61 328 61 49</phone>
      <email>walter.weber@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Weber, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Spital</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dieter Müller, MD</last_name>
      <phone>+41 61 823 77 00</phone>
      <email>dieter.müller@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Dieter Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOSI - Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerio Arcangelo Vitale, MD</last_name>
      <phone>+41 91 811 76 73</phone>
      <email>valerioarcangelo.vitale@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Valerio Arcangelo Vitale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitätsklinik für Frauenklinik</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Rauh, MD</last_name>
      <phone>+41 31 632 9686</phone>
      <email>claudia.rauh@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Claudia Rauh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Brustzentrum Bern Biel</name>
      <address>
        <city>Bern</city>
        <zip>3013</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Sager, MD</last_name>
      <phone>+41 31 337 89 70</phone>
      <email>patrizia.sager@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Patrizia Sager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Gabriella Maranta, MD</last_name>
      <phone>+41 81 254 81 53</phone>
      <email>martina.maranta@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Martina Gabriella Maranta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Thurgau</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Fehr, Prof</last_name>
      <phone>+41 52 723 72 56</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Fehr, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Kohlik, MD</last_name>
      <phone>+41 22 362 60 00</phone>
      <email>mkohlik@genolier.net</email>
    </contact>
    <investigator>
      <last_name>Magdalena Kohlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Kurtz, MD</last_name>
      <phone>+41 41 205 13 42</phone>
      <email>claudia.kurtz@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Claudia Kurtz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Dubsky, MD</last_name>
      <phone>+41 41 208 37 54</phone>
      <email>peter.dubsky@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Peter Dubsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum Fricktal</name>
      <address>
        <city>Rheinfelden</city>
        <zip>4130</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maik Hauschild, MD</last_name>
      <phone>+41 61 835 62 20</phone>
      <email>maik.hauschild@gzf.ch</email>
    </contact>
    <investigator>
      <last_name>Maik Hauschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor- und Brustzentrum ZeTuP St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Dupont-Lampert, MD</last_name>
      <phone>+41 71 243 00 43</phone>
      <email>Veronique.dupont@zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Véronique Dupont-Lampert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Strub, MD</last_name>
      <phone>+41 71 494 97 14</phone>
      <email>christine.strub@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Christine Strub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>St. Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Knauer, MD</last_name>
      <phone>+41 71 552 33 33</phone>
      <email>michael.knauer@bz-ost.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Knauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brust-Zentrum Seefeld</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Tausch, MD</last_name>
      <phone>+41 44 380 76 60</phone>
      <email>c.tausch@brust-zentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Christoph Tausch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>VISION I</keyword>
  <keyword>breast cancer</keyword>
  <keyword>Vacuum assisted biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

